Lucey Olivia, Potter Jessica, Ricketts William, Castle Lianne, Melzer Mark
Division of Infection, Barts Health NHS Trust, 80 Newark Street,Whitechapel, London E1 2ES, United Kingdom; Department of Infectious Diseases, Imperial College London, South Kensington, London, United Kingdom.
Department of Respiratory Medicine, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
J Infect. 2022 Jan;84(1):17-23. doi: 10.1016/j.jinf.2021.10.015. Epub 2021 Oct 24.
To characterise and describe the diagnostic utility of Endobronchial ultrasound-transbronchial needle aspiration (EBUS-TBNA) in intrathoracic tuberculosis in a cohort of patients with mediastinal lymphadenopathy of unknown aetiology.
Consecutive patients with intrathoracic lymphadenopathy undergoing EBUS-TBNA between 2012 and 2016 were identified. Demographic data, biopsy cytopathology and mycobacteriology results, HIV and vitamin D status, susceptibility results and final diagnoses were recorded. Pre- and post-procedure probability scores were assigned to each case to reflect the probability of tuberculosis.
315 cases were identified; 54 (17.1%) had tuberculosis and 261 (82.9%) had a non-tuberculosis diagnosis. amongst TB cases, the sensitivity of EBUS-TBNA was 59.3% (95% CI 45.06-72.14), specificity 100% (95% CI 98.19-100) and the negative predictive value (NPV) was 92.23% (95% CI 88.31-94.95). 19/54 (35%) TB cases were confirmed by EBUS mycobacterial culture and 13/54 (24.1%) by cytopathology. 33 (61.1%) of the TB cases, had a low to medium pre-test probability score assigned prior to EBUS-TBNA. Amongst EBUS culture-confirmed cases, we found a resistance rate of 10.5% to one or more first line TB drugs, with one case of multi-drug resistant TB.
We confirmed the utility of EBUS-TBNA in the diagnosis of intrathoracic tuberculosis in an undifferentiated cohort of patients with mediastinal lymphadenopathy of unknown aetiology and advocate sending samples for mycobacterial culture in all cases in high tuberculosis incidence areas.
在一组病因不明的纵隔淋巴结肿大患者中,对支气管内超声引导下经支气管针吸活检术(EBUS-TBNA)在诊断胸内结核中的应用特点及效用进行描述。
确定2012年至2016年间连续接受EBUS-TBNA检查的胸内淋巴结肿大患者。记录人口统计学数据、活检细胞病理学和分枝杆菌学结果、HIV和维生素D状态、药敏结果及最终诊断。为每个病例分配术前和术后概率评分以反映结核病的可能性。
共确定315例病例;54例(17.1%)患有结核病,261例(82.9%)诊断为非结核病。在结核病病例中,EBUS-TBNA的敏感性为59.3%(95%置信区间45.06 - 72.14),特异性为100%(95%置信区间98.19 - 100),阴性预测值(NPV)为92.23%(95%置信区间88.31 - 94.95)。19/54(35%)的结核病病例通过EBUS分枝杆菌培养确诊,13/54(24.1%)通过细胞病理学确诊。33例(61.1%)结核病病例在EBUS-TBNA术前被赋予低至中等的预测试概率评分。在EBUS培养确诊的病例中,我们发现对一种或多种一线抗结核药物的耐药率为10.5%,其中有1例耐多药结核病。
我们证实了EBUS-TBNA在诊断病因不明的纵隔淋巴结肿大未分化患者群体胸内结核中的效用,并主张在结核病高发地区对所有病例都送检样本进行分枝杆菌培养。